Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$268.46 -0.9%	$259.86	$141.98 ▼ $304.39	$35.26B	0.39	830,396 shs	683,886 shs
BIIB Biogen	$138.37 -1.4%	$141.88	$128.51 ▼ $238.00	$20.25B	0.01	1.30 million shs	1.09 million shs
BMY Bristol-Myers Squibb	$60.10 +2.0%	$58.55	$39.35 ▼ $63.33	$121.96B	0.43	12.75 million shs	10.79 million shs
JNJ Johnson & Johnson	$163.63 +0.3%	$158.68	$140.68 ▼ $169.99	$394.32B	0.47	7.63 million shs	5.76 million shs
LEGN Legend Biotech	$35.06 -0.9%	$36.44	$30.17 ▼ $60.87	$6.44B	0.19	1.19 million shs	504,807 shs
MRKR Marker Therapeutics	$1.27 -7.3%	$1.63	$1.13 ▼ $5.99	$13.60M	1.51	58,693 shs	38,420 shs
NVS Novartis	$112.69 +1.2%	$107.92	$92.35 ▼ $120.92	$227.70B	0.53	1.49 million shs	2.54 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-5.25%	+13.19%	+12.81%	+73.88%
BIIB Biogen	0.00%	-1.80%	-1.08%	-8.55%	-36.04%
BMY Bristol-Myers Squibb	0.00%	-1.58%	+2.25%	+4.19%	+12.86%
JNJ Johnson & Johnson	0.00%	+0.14%	-0.04%	+12.81%	+3.59%
LEGN Legend Biotech	0.00%	-5.12%	-4.51%	+7.91%	-38.42%
MRKR Marker Therapeutics	0.00%	+1.60%	-16.72%	-63.61%	-70.70%
NVS Novartis	0.00%	+0.52%	+3.47%	+14.54%	+17.54%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.2401 of 5 stars	3.4	3.0	0.0	4.3	2.7	2.5	0.6
BIIB Biogen	4.8974 of 5 stars	4.2	5.0	0.0	3.7	3.3	2.5	1.9
BMY Bristol-Myers Squibb	3.8729 of 5 stars	1.2	3.0	4.2	4.0	3.5	3.3	0.0
JNJ Johnson & Johnson	4.4007 of 5 stars	2.3	3.0	4.2	3.9	3.5	2.5	0.6
LEGN Legend Biotech	2.8553 of 5 stars	3.5	3.0	0.0	0.0	3.6	1.7	0.6
MRKR Marker Therapeutics	3.9373 of 5 stars	3.7	3.0	0.0	3.9	1.9	0.8	0.6
NVS Novartis	2.3055 of 5 stars	0.9	5.0	2.5	0.0	4.0	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.76	Moderate Buy	$312.30	16.33% Upside
BIIB Biogen	2.43	Hold	$213.33	54.18% Upside
BMY Bristol-Myers Squibb	2.32	Hold	$57.86	-3.73% Downside
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	4.71% Upside
LEGN Legend Biotech	2.92	Moderate Buy	$79.00	125.33% Upside
MRKR Marker Therapeutics	3.33	Buy	$13.50	962.99% Upside
NVS Novartis	1.80	Reduce	$123.38	9.48% Upside

Current Analyst Ratings Breakdown

Latest LEGN, JNJ, BMY, NVS, BIIB, ALNY, and MRKR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/24/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$280.00 ➝ $328.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$338.00 ➝ $351.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$385.00 ➝ $390.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$310.00 ➝ $330.00
3/21/2025	ALNY Alnylam Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/21/2025	ALNY Alnylam Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$300.00 ➝ $338.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$275.00 ➝ $287.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$300.00 ➝ $300.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$302.00 ➝ $325.00
3/17/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$82.00 ➝ $80.00

(Data available from 3/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	15.53	N/A	N/A	$0.52 per share	516.27
BIIB Biogen	$9.68B	2.09	$22.72 per share	6.09	$114.71 per share	1.21
BMY Bristol-Myers Squibb	$48.30B	2.53	$6.34 per share	9.48	$8.08 per share	7.44
JNJ Johnson & Johnson	$88.82B	4.44	$13.45 per share	12.17	$29.69 per share	5.51
LEGN Legend Biotech	$627.24M	10.27	N/A	N/A	$6.88 per share	5.10
MRKR Marker Therapeutics	$3.31M	4.11	N/A	N/A	$1.58 per share	0.80
NVS Novartis	$51.72B	4.45	$11.24 per share	10.03	$21.59 per share	5.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.17	N/A	301.64	N/A	-12.37%	N/A	-6.83%	5/1/2025 (Estimated)
BIIB Biogen	$1.63B	$11.19	12.37	8.38	1.51	16.87%	14.98%	8.76%	4/23/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	-$4.42	N/A	9.87	2.07	-18.53%	13.93%	2.46%	4/24/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$6.65	24.61	14.78	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
LEGN Legend Biotech	-$518.25M	-$0.48	N/A	N/A	N/A	-66.92%	-29.69%	-19.45%	5/12/2025 (Estimated)
MRKR Marker Therapeutics	-$8.24M	N/A	0.00	N/A	N/A	-179.74%	-89.63%	-71.62%	3/31/2025 (Estimated)
NVS Novartis	$11.94B	$5.88	19.17	12.79	1.70	23.56%	37.24%	15.85%	4/22/2025 (Estimated)

Latest LEGN, JNJ, BMY, NVS, BIIB, ALNY, and MRKR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/24/2025	N/A	BMY Bristol-Myers Squibb	$1.55	N/A	N/A	N/A	$10.77 billion	N/A
4/23/2025	N/A	BIIB Biogen	$3.59	N/A	N/A	N/A	$2.25 billion	N/A
4/22/2025	N/A	NVS Novartis	$2.07	N/A	N/A	N/A	N/A	N/A
4/15/2025	N/A	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
3/31/2025	N/A	MRKR Marker Therapeutics	-$0.28	-$0.22	+$0.06	N/A	$5.25 million	$1.22 million
3/11/2025	Q4 2024	LEGN Legend Biotech	-$0.39	$0.07	+$0.46	$0.07	$179.00 million	$186.50 million
2/13/2025	Q4 2024	ALNY Alnylam Pharmaceuticals	-$0.62	-$0.65	-$0.03	-$0.65	$580.62 million	N/A
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
1/31/2025	Q4 2024	NVS Novartis	$1.80	$1.98	+$0.18	$1.41	$12.86 billion	N/A
1/22/2025	Q4 2024	JNJ Johnson & Johnson	$1.99	$2.04	+$0.05	$1.41	$22.44 billion	$22.52 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BMY Bristol-Myers Squibb	$2.48	4.13%	+6.38%	N/A	17 Years
JNJ Johnson & Johnson	$4.96	3.03%	+5.43%	74.59%	63 Years
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
NVS Novartis	$2.51	2.23%	+5.34%	42.69%	N/A

Latest LEGN, JNJ, BMY, NVS, BIIB, ALNY, and MRKR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025
2/20/2025	NVS Novartis		$3.8695		3/12/2025	3/12/2025	3/12/2025
1/2/2025	JNJ Johnson & Johnson	quarterly	$1.24	3.43%	2/18/2025	2/18/2025	3/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	15.27	2.78	2.71
BIIB Biogen	0.27	1.35	0.90
BMY Bristol-Myers Squibb	2.90	1.25	1.15
JNJ Johnson & Johnson	0.43	1.11	0.86
LEGN Legend Biotech	0.27	4.98	4.90
MRKR Marker Therapeutics	N/A	3.15	3.15
NVS Novartis	0.48	1.04	0.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
BMY Bristol-Myers Squibb	76.41%
JNJ Johnson & Johnson	69.55%
LEGN Legend Biotech	70.89%
MRKR Marker Therapeutics	22.39%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
BIIB Biogen	0.16%
BMY Bristol-Myers Squibb	0.09%
JNJ Johnson & Johnson	0.16%
LEGN Legend Biotech	0.02%
MRKR Marker Therapeutics	14.50%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,000	130.09 million	127.52 million	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
BMY Bristol-Myers Squibb	34,300	2.03 billion	2.03 billion	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
LEGN Legend Biotech	1,070	183.65 million	182.60 million	Optionable
MRKR Marker Therapeutics	60	10.71 million	9.16 million	Not Optionable
NVS Novartis	101,700	2.04 billion	2.04 billion	Optionable

LEGN, JNJ, BMY, NVS, BIIB, ALNY, and MRKR Headlines

Recent News About These Companies

Tucker Asset Management LLC Boosts Stake in Novartis AG (NYSE:NVS)

March 30 at 7:17 AM | marketbeat.com

Novartis AG (NYSE:NVS) Shares Acquired by LPL Financial LLC

March 30 at 4:14 AM | marketbeat.com

Financial Engines Advisors L.L.C. Purchases Shares of 3,640 Novartis AG (NYSE:NVS)

March 29 at 5:12 AM | marketbeat.com

Novartis AG (NYSE:NVS) Receives Average Rating of "Reduce" from Brokerages

March 29 at 4:32 AM | marketbeat.com

American Century Companies Inc. Has $44.12 Million Stake in Novartis AG (NYSE:NVS)

March 29 at 4:10 AM | marketbeat.com

FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto

March 28 at 3:39 PM | appliedclinicaltrialsonline.com

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

March 28 at 12:52 PM | globenewswire.com

Here's Why Novartis (NVS) is a Strong Value Stock

March 28 at 10:40 AM | zacks.com

Novartis AG (NYSE:NVS) Shares Sold by Loomis Sayles & Co. L P

March 28 at 6:48 AM | marketbeat.com

Proficio Capital Partners LLC Buys Shares of 2,312 Novartis AG (NYSE:NVS)

March 28 at 3:20 AM | marketbeat.com

Congress Wealth Management LLC DE Sells 22,499 Shares of Novartis AG (NYSE:NVS)

March 27 at 4:48 AM | marketbeat.com

Wambolt & Associates LLC Has $2.59 Million Holdings in Novartis AG (NYSE:NVS)

March 26, 2025 | marketbeat.com

Novartis put volume heavy and directionally bearish

March 26, 2025 | markets.businessinsider.com

CoreFirst Bank & Trust Buys Shares of 2,310 Novartis AG (NYSE:NVS)

March 26, 2025 | marketbeat.com

Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

March 25, 2025 | pmlive.com

5 Large Drug Stocks to Watch as Industry Recovers

March 25, 2025 | zacks.com

Mill Capital Management LLC Cuts Stock Position in Novartis AG (NYSE:NVS)

March 25, 2025 | marketbeat.com

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

March 25, 2025 | globenewswire.com

Chinese VP meets Swire Pacific Limited chairman, Novartis CEO

March 24, 2025 | chinaview.cn

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

March 24, 2025 | zacks.com

Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

March 24, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality
By Jeffrey Neal Johnson | March 10, 2025
View Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality
Resilient Investing: 3 Stocks Built to Weather Market Volatility
By Jeffrey Neal Johnson | March 17, 2025
View Resilient Investing: 3 Stocks Built to Weather Market Volatility

LEGN, JNJ, BMY, NVS, BIIB, ALNY, and MRKR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$268.46 -2.56 (-0.94%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$266.52 -1.94 (-0.72%)

As of 03/28/2025 07:58 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$138.37 -1.96 (-1.40%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$137.85 -0.52 (-0.37%)

As of 03/28/2025 07:49 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Bristol-Myers Squibb NYSE:BMY

$60.10 +1.20 (+2.04%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$59.96 -0.13 (-0.22%)

As of 03/28/2025 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Johnson & Johnson NYSE:JNJ

$163.63 +0.50 (+0.31%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$163.36 -0.27 (-0.17%)

As of 03/28/2025 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Legend Biotech NASDAQ:LEGN

$35.06 -0.33 (-0.93%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$35.10 +0.04 (+0.11%)

As of 03/28/2025 04:10 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Marker Therapeutics NASDAQ:MRKR

$1.27 -0.10 (-7.30%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$1.27 +0.00 (+0.39%)

As of 03/28/2025 06:38 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Novartis NYSE:NVS

$112.69 +1.29 (+1.16%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$113.99 +1.30 (+1.15%)

As of 03/28/2025 07:52 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEGN, JNJ, BMY, NVS, BIIB, ALNY, and MRKR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEGN, JNJ, BMY, NVS, BIIB, ALNY, and MRKR Earnings

Compare Dividends

Latest LEGN, JNJ, BMY, NVS, BIIB, ALNY, and MRKR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEGN, JNJ, BMY, NVS, BIIB, ALNY, and MRKR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LEGN, JNJ, BMY, NVS, BIIB, ALNY, and MRKR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Bristol-Myers Squibb NYSE:BMY

Johnson & Johnson NYSE:JNJ

Legend Biotech NASDAQ:LEGN

Marker Therapeutics NASDAQ:MRKR

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools